Jagsonpal Pharmaceuticals has informed that Pursuant to Regulation 8 & 9 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015, the Company has submitted the Code of Practices and procedures for fair disclosure of Unpublished Price Sensitive Information.
The above information is a part of company’s filings submitted to BSE.